The slow light sensor techniques have been applied to bio-related detection in the past decades. However, similar testing-systems are too large to carry to a remote area for diagnosis or point-of-care testing. This study demonstrated a fully automatic portable biosensing system based on the microring resonator. An optical-fiber array mounted on a controller based micro-positioning system, which can be interfaced with MATLAB to locate a tentative position for light source and waveguide coupling alignment. Chip adapter and microfluidic channel could be packaged as a product such that it is cheap to be manufactured and can be disposed of after every test conducted. Thus, the platform can be more easily operated via an ordinary user without expertise in photonics. It is designed based on conventional optical communication wavelength range. The C-band superluminescent-light-emitting-diode light source couples in/out the microring sensor to obtain quasi-TE mode by grating coupler techniques. For keeping a stable chemical binding reaction, the cost-effective microfluidic pump was developed to offer a specific flow rate of 20 μL/min by using a servo-motor, an Arduino board, and a motor driver. The subwavelength grating metamaterial ring resonator shows highly sensitive sensing performance via surface index changes due to biomarker adhered on the sensor. The real-time peak-shift monitoring shows 10 μg/mL streptavidin detection of limit based on the biotin-streptavidin binding reaction. Through the different specific receptors immobilized on the sensor surface, the system can be utilized on the open applications such as heavy metal detection, gas sensing, virus examination, and cancer marker diagnosis.
1 August 2018 in Sensors and Actuators B: Chemical
In the clinical trials, AlGaN/GaN HEMT biosensors were successfully investigated for the rapid detection of CA 19-9 tumor markers. Our strategy involves using a normalized resistance change ratio, which helps to minimize uncertainties associated with material variances, chemical functionalization interferences, and device fabrication allowances. Anchored at a "37 U/mL CA 19-9 baseline," our approach significantly improves screening efficiency and reliability for both normal and cancerous concentrations. Validation was conducted using 35 clinical serum specimens obtained from both healthy individuals and cancer patients. Among these, 33 specimens exhibited the expected response to the standard value of 37 U/mL, resulting in an accuracy rate of 94%. Furthermore, we have included detection data for standard CEA to provide insights into future possibilities for chiplets that facilitate the simultaneous detection of multiple biomarkers, offering versatility and efficiency.